NASDAQ:MNOV MediciNova (MNOV) Stock Price, News & Analysis → How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad) Free MNOV Stock Alerts $1.31 -0.01 (-0.76%) (As of 12:48 PM ET) Add Compare Share Share Today's Range$1.30▼$1.3650-Day Range$1.28▼$1.5752-Week Range$1.26▼$2.66Volume5,157 shsAverage Volume51,461 shsMarket Capitalization$64.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MediciNova alerts: Email Address MediciNova MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.80Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.45 out of 5 starsMedical Sector875th out of 908 stocksPharmaceutical Preparations Industry411th out of 424 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MediciNova. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.53% of the float of MediciNova has been sold short.Short Interest Ratio / Days to CoverMediciNova has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in MediciNova has recently decreased by 25.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediciNova does not currently pay a dividend.Dividend GrowthMediciNova does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNOV. Previous Next 3.2 News and Social Media Coverage News SentimentMediciNova has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MediciNova this week, compared to 0 articles on an average week.Search Interest2 people have searched for MNOV on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediciNova insiders have not sold or bought any company stock.Percentage Held by Insiders16.90% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.90% of the stock of MediciNova is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediciNova are expected to decrease in the coming year, from ($0.23) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediciNova is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediciNova is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediciNova has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About MediciNova Stock (NASDAQ:MNOV)MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Read More MNOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNOV Stock News HeadlinesApril 21, 2024 | americanbankingnews.comStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)April 2, 2024 | globenewswire.comMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)April 26, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! March 27, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 27, 2024 | msn.comPre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…March 27, 2024 | marketwatch.comMediciNova Gets Patent in Japan for Multiple Sclerosis-Related TreatmentMarch 27, 2024 | tmcnet.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 26, 2024 | globenewswire.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanApril 26, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! March 20, 2024 | globenewswire.comMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis SocietyMarch 20, 2024 | finance.yahoo.comCompanies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In GrowthMarch 12, 2024 | globenewswire.comMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of ToxicologyFebruary 29, 2024 | finance.yahoo.comMNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…February 28, 2024 | money.usnews.comMedicinova IncJanuary 17, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaJanuary 17, 2024 | finance.yahoo.comMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaDecember 21, 2023 | finance.yahoo.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of ToxicologyDecember 6, 2023 | markets.businessinsider.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeDecember 6, 2023 | finance.yahoo.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeNovember 27, 2023 | finance.yahoo.comMNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…November 22, 2023 | finance.yahoo.comThe past five years for MediciNova (NASDAQ:MNOV) investors has not been profitableNovember 20, 2023 | msn.comWhy Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?November 19, 2023 | finance.yahoo.comMediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-OncologyOctober 28, 2023 | benzinga.comMediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 27, 2023 | finance.yahoo.comMediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 12, 2023 | finance.yahoo.comWe're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash WiselyOctober 10, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in CanadaSee More Headlines Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees13Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net MarginsN/A Pretax Margin-856.80% Return on Equity-13.19% Return on Assets-12.50% Debt Debt-to-Equity RatioN/A Current Ratio15.61 Quick Ratio15.61 Sales & Book Value Annual Sales$1 million Price / Sales64.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book1.04Miscellaneous Outstanding Shares49,050,000Free Float40,757,000Market Cap$64.75 million OptionableOptionable Beta0.75 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Yuichi Iwaki M.D. (Age 74)Ph.D., Co-Founder, President, CEO & Executive Director Comp: $933.05kDr. Kazuko Matsuda M.D. (Age 58)M.P.H., Ph.D., Chief Medical Officer & Director Comp: $653.65kMr. Jason J. Kruger CPA (Age 46)CFO & Principal Financial Officer Dr. David H. Crean M.B.A. (Age 59)Ph.D., Chief Business Officer Mr. John O'Neil CPAControllerKey CompetitorsRallybioNASDAQ:RLYBViveon Health AcquisitionNYSE:VHAQCelularityNASDAQ:CELULantern PharmaNASDAQ:LTRNEagle PharmaceuticalsNASDAQ:EGRXView All CompetitorsInstitutional OwnershipBank Julius Baer & Co. Ltd ZurichBought 19,000 shares on 2/2/2024Ownership: 0.039%Simplex Trading LLCBought 700 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions MNOV Stock Analysis - Frequently Asked Questions How have MNOV shares performed in 2024? MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV stock has decreased by 12.0% and is now trading at $1.32. View the best growth stocks for 2024 here. Are investors shorting MediciNova? MediciNova saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 247,000 shares, a drop of 26.0% from the March 31st total of 333,600 shares. Based on an average trading volume of 49,400 shares, the days-to-cover ratio is currently 5.0 days. Currently, 0.5% of the shares of the stock are sold short. View MediciNova's Short Interest. When is MediciNova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MNOV earnings forecast. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY). How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MNOV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
